Hedge Funds Shift Positions on AbbVie: Analysis of 13F Filings

Hedge funds are adjusting their positions on AbbVie (ABBV), with a slight overall increase in holdings. This trend suggests cautious optimism, indicating potential for future price stability within the next 1-3 months.

Date: 12-05-2025

AI Rating: 6

In the latest 13F filings, AbbVie Inc (Symbol: ABBV) has caught the attention of professional investors due to a noticeable shift in hedge fund positions. A total of 18 funds held ABBV stock, with mixed movements reported across their positions. While 4 funds increased their positions, 11 decreased theirs. The net effect was an aggregate increase of approximately 0.97% in shares held, totaling over 546 million shares by the end of the reporting period. This signals a cautious yet measured confidence in AbbVie by a select group of hedge funds.

Aggregate Position Changes: The overall sentiment among funds appears to be a mix of consolidation and selective accumulation. Notably, the top three holders, including Vanguard Group Inc and BlackRock Inc, contribute significantly to the stable base of support around the stock. However, the decrease in positions by the majority suggests that concerns may exist regarding short-term performance, likely driven by ongoing market volatility and sector-specific challenges.

Given the aggregate increase in shares, despite the number of funds reducing their holdings, investors may view this trend as a signal of long-term stability with potential for positive returns in the coming months. However, it’s essential for investors to keep a close watch on AbbVie's performance metrics including earnings and revenue trends, as these will critically influence investor perception moving forward.

Stocks: ABBV